TEM · Tempus AI, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $8M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net income (loss) 5.64M
-3.9M Interest income
+10.28M Interest expense
+7.13M Depreciation
+18.86M Amortization
+309K Provision for (benefit from) income taxes
+2.86M Losses from equity method investments
-97.4M Fair value changes
+54.12M Stock-based compensation expense
+1.49M Employer payroll tax related to stock-based compensation
+990K Acquisition related expenses
-3.99M Amortization of technology license
+0K Franchise taxes related to IPO
+11.64M Loss on debt extinguishment
= Adjusted EBITDA 8.04M
|
|||
| Hereditary revenue growth | 5% | Q2 2026 | — |
| MRD volume | 9,000 | Q2 2026 | — |
|
|
|||
| Oncology volume growth | 31% | Q2 2026 | — |
|
|
|||
| Hereditary volume growth | 54% | Q1 2026 | — |
| Non-GAAP gross margin non-GAAP | 65% | Three Months Ended March 31, 2026 | — |
| Non-GAAP gross margin, data and applications non-GAAP | 73.1% | Three Months Ended March 31, 2026 | — |
| Non-GAAP gross margin, diagnostics non-GAAP | 62.3% | Three Months Ended March 31, 2026 | — |
| Non-GAAP gross profit non-GAAP | $226.23M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Gross profit 222.04M
+3.68M Stock-based compensation expense
+518K Employer payroll tax related to stock-based compensation
= Non-GAAP gross profit 226.23M
|
|||
| Non-GAAP gross profit, data and applications non-GAAP | $63.64M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Gross profit, data and applications 61.9M
+1.55M Stock-based compensation expense
+184K Employer payroll tax related to stock-based compensation
= Non-GAAP gross profit, data and applications 63.64M
|
|||
| Non-GAAP operating expenses non-GAAP | $237.81M | Three Months Ended March 31, 2026 | — |
| Non-GAAP research and development non-GAAP | $43.19M | Three Months Ended March 31, 2026 | — |
| Non-GAAP selling, general and administrative non-GAAP | $159.02M | Three Months Ended March 31, 2026 | — |
| Non-GAAP technology research and development non-GAAP | $35.6M | Three Months Ended March 31, 2026 | — |
| Net Revenue Retention | 126% | Full Year 2025 | — |
| Total Remaining Contract Value | 1.1B | Full Year 2025 | — |
| Total Contract Value (TCV) | 1.1B | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TEM
this stock
Tempus AI, Inc.
|
$12.36B | +19.7% | +83.4% | — | 16.6% |
|
VEEV
Veeva Systems Inc
|
$39.78B | +26.4% | +28.1% | 43.4 | 3.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$13.02B | -24.9% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.25B | +62.6% | +28.2% | 37.5 | 4.5% |
|
TXG
10x Genomics, Inc.
|
$8.37B | +297.6% | +68.1% | — | 12.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TEM | +6.1% | +59.6% | +35.3% | +61.1% | +19.7% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +5.0% | +55.6% | +20.6% | +57.9% | +6.6% |